BioSpace News Archive

Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.

Biopharma and life sciences companies provide updates on their pipelines and business plans.

Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.

Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.

New information released Tuesday by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19. In addition, 70% of these products are in the discovery or preclinical stages.

Speaking before Congress on Tuesday, Dr. Anthony Fauci urged people to adopt strategies that involve wearing a mask in public, maintaining social distance and avoiding large gatherings of people.

Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs.

COVID-19-related testimonies will continue in Congress today, with representatives from the Biotechnology Innovation Organization (BIO) expected to address the current pandemic as well as key priorities that will need to be in place in order to effectively respond to the next global viral threat.

Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces the appointment of Dr. Leila Alland and Ms. Jane Wasman to its Board of Directors, effective immediately. Dr. Leila Alland brings extensive experience in oncology drug development to her role at Cytovia Therapeutics. Dr. Alland is currently Chief Medical Officer at PMV Pharma, a leader in the discov

Fewer Than One Percent of All Rated Organizations Have Received the Distinction With This Consistency